Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials by Seligmann, JF et al.
This is a repository copy of Investigating the poor outcomes of BRAF - mutant advanced 
colorectal cancer: Analysis from 2530 patients in randomised clinical trials.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/110632/
Version: Accepted Version
Article:
Seligmann, JF, Fisher, D, Smith, CG et al. (9 more authors) (2017) Investigating the poor 
outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in 
randomised clinical trials. Annals of Oncology, 28 (3). pp. 562-568. ISSN 0923-7534 
https://doi.org/10.1093/annonc/mdw645
© The Author(s) 2016. Published by Oxford University Press on behalf of the European 
Society for Medical Oncology. All rights reserved. This is a pre-copyedited, 
author-produced PDF of an article accepted for publication in Annals of Oncology following
peer review. The version of record, 'Seligmann, JF, Fisher, D, Smith, CG et al (2017) 
Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis 
from 2530 patients in randomised clinical trials. Annals of Oncology, 28 (3). pp. 562-568,' is
available online at: https://doi.org/10.1093/annonc/mdw645. Uploaded in accordance with 
the publisher's self-archiving policy.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 1 
Investigating the poor outcomes of BRAF-mutant advanced colorectal 
cancer: Analysis from 2530 patients in randomised clinical trials  
 
J.F. Seligmann1, D. Fisher2, C.G. Smith3, S.D. Richman1, F. Elliott1, S. 
Brown4, R. Adams3, T. Maughan5, P. Quirke1, J. Cheadle3, M. Seymour1* and 
G. Middleton6*. 
 
Corresponding Author 
 
Professor Gary Middleton 
Institute of Immunology and Immunotherapy, University of Birmingham and 
University Hospital Birmingham, UK 
Tel: 44 7789502237 
Email: G.Middleton@bham.ac.uk 
 
Affiliations 
 
1. Leeds Institute of Cancer and Pathology, University of Leeds, St. James’s 
University Hospital, Beckett St., Leeds, United Kingdom; 
2. Medical Research Council Clinical Trials Unit, University College London, 
London, United Kingdom; 
3. Institute of Medical Genetics, Institute of Cancer and Genetics, Cardiff 
University, Cardiff, United Kingdom; 
4. Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, 
United Kingdom; 
5. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, 
Oxford, United Kingdom; 
6. Institute of Immunology and Immunotherapy, University of Birmingham and 
University Hospital Birmingham, UK. 
* MTS and GM are joint senior authors 
 
 
Word count: 3609 
  
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical 
Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 
 Annals of Oncology Advance Access published December 19, 2016
 at U
niversity of Birm
ingham
 on D
ecem
ber 20, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
 2 

	

To improve strategies for the treatment ofmutant advanced colorectal 
cancer (aCRC) patients we examined individual data from patients treated 
with chemotherapy alone in three randomised trials to identify points on the 
treatment pathway where outcomes differ from  wildBtypes. 
 

2530 aCRC patients were assessed from three randomised trials. EndBpoints 
were progression free survival (PFS), response rate (RR), disease control rate 
(DCR), postBprogression survival (PBPS) and overall survival (OS). 
Treatments included firstBline oxaliplatin/fluorouracil (OxFU), and secondBline 
irinotecan. Clinicians were unaware of Bstatus 
 

231 patients (9.1%) had Bmutant tumours. mutation conferred 
significantly worse survival independent of associated clinicopathological 
factors known to be prognostic. Compared with wildBtype, Bmutant 
patients treated with firstBline OxFU had similar DCR (59.2% vs 72%; adjusted 
OR=0.76,p=0.24) and PFS (5.7 vs 6.3 months; adjusted HR=1.14, p=0.26). 
Following progression on firstBline chemotherapy, Bmutant patients had 
a markedly shorter PBPS (4.2 vs 9.2 months, adjusted HR=1.69,p<0.001).  
 
Fewer Bmutant patients received secondBline treatment (33%  51%, 
p<0.001), but Bmutation was not associated with inferior secondBline 
outcomes (RR adjusted OR=0.56, p=0.45; PFS adjusted HR=1.01, p=0.93). 
 
Significant clinical heterogeneity within the Bmutant population was 
observed: a proportion (24.3%) had good firstBline PFS and PBPS (both >6 
months; OS=24.0 months), however 36.5% progressed rapidly through firstB
line chemotherapy and thereafter, with OS=4.7 months. 
  

 
Bmutant aCRC confers a markedly worse prognosis independent of 
associated clinicopathological features. Chemotherapy provides meaningful 
improvements in outcome throughout treatment lines. PostBprogression 
survival is markedly worse and vigilance is required to ensure appropriate 
delivery of treatment after firstBline progression.  
 

Colorectal cancer; Bmutant; chemotherapy; prognosis 
 
 


We show that BRAFBmutant aCRC patients derive similar relative benefit from 
chemotherapy as wildBtypes. The point at which outcomes differ is following 
progression on firstBline chemotherapy. Significant clinical heterogeneity was 
observed and efforts should be concentrated on identifying BRAFBmutant 
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 3 
patients who benefit from chemotherapy, and alternative strategies tested for 
those who don't. 
 
INTRODUCTION 
 
The V600E activating mutation in   (mutant) is found in the 
tumours of 8B12% patients with advanced colorectal cancer (aCRC). B
mutant aCRC is consistently associated with poor overall survival (OS) and 
progression free survival (PFS) in case series[1] and randomised controlled 
trials (RCTs).[2] In a recent RCT of previously untreated aCRC, median OS 
was 13.4 months in Bmutant patients compared with 37.1 months in 
	 and  wildBtypes.[3]   
 
The mechanism for the poor prognosis is poorly understood, and it is unclear 
at what point in the aCRC treatment pathway that Bmutant outcomes 
diverge from wildBtypes; whilst OS is uniformly poor, less impact is seen with 
PFS compared with wildBtypes.[4,5] It has been hypothesised that poor 
outcomes are secondary to intrinisc chemoresistance but there is a paucity of 
data describing the outcomes of Bmutant aCRC with chemotherapy 
alone, particularly beyond the firstBline. This is particularly important as B
mutant patients have questionable benefit from antiBepidermal growth factor 
receptor (antiBEGFR) therapies[6] and Btargeted strategies have yet to 
make clinical impact in aCRC.[7,8] 
 
Importantly previous publications have not performed careful multivariate 
analysis. This is critical as Bmutant aCRC is associated with 
clinicopathological features which are themselves negative prognostic 
factors,[9] including defective mismatch repair (dMMR) status[4,10], right sided 
primary tumour location (PTL)[11] and a high incidence of peritoneal 
metastases.[12] The observed poor outcomes may instead be driven by such 
factors so it is essential to prospectively factor this into analyses of outcomes.  
 
This paper provides detailed analysis of the natural history of Bmutant 
aCRC to give more clarity about prognosis and an evidence base to 
quantitate the benefits of different chemotherapy strategies throughout the 
treatment pathway.  
 
In a preBplanned analysis we have examined individual patient data from three 
RCTs to identify points on the treatment pathway at which Bmutant 
outcomes differ from  wildBtype patients treated with cytotoxic 
chemotherapy, to assess the impact of potential confounders and to provide 
clinicians with detailed information of outcomes with various chemotherapy 
strategies. We analysed treatment outcomes in two firstBline RCTs with 
oxaliplatin/fluorouracil (OxFU), behaviour during chemotherapyBfree intervals 
and following disease progression. We then report patterns of, and outcomes 
with secondBline therapy. In order to avoid potential interactions of  
status with antiBEGFR drugs we focus on patients treated in arms that did not 
include targeted therapies. Potential confounding factors were prospectively 
identified, and analyses adjusted accordingly. Bstatus was unknown to 
clinicians treating patients in each trial, eliminating potential bias. 
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%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Individual patient data were obtained from selected arms of three large 
randomised trials (FOCUS [ISRCTN 79877428],[13] COIN [ISRCTN 
27286448],[14,15] PICCOLO [ISRCTN 93248876][16,17] to reflect different clinical 
uses of standard cytotoxic chemotherapy (without targeted therapy) in aCRC 
(Supplementary Figure 1).  
 
Inclusion criteria for FOCUS and COIN were consistent. National ethical 
approval and patient consent was obtained for all aspects of the clinical and 
translational research. DNA extraction and genotyping for mutations including 
V600E was performed retrospectively as previously reported.
[16,18,19] 
 
!
 
Stata was used (


,StataCorp). Baseline patient 
characteristics were compared between Bmutant patients (with or 
without other MEK/AKT pathway mutations) and wildBtype patients 
using twoBtailed TBtests, Wilcoxon rank sum tests and Pearson ChiBsquared 
tests. 
 
Endpoints used were OS (time from randomisation to death from any cause), 
PFS (time from randomisation to first evidence of progression or death); 12B
week RECIST response rate (RR), and disease control rate (DCR).[20] Finally, 
we compared postBprogression survival time (PBPS), defined as time from 
progression to death in those with a progression event, however when date of 
progression data was unavailable date of last chemotherapy cycle was used 
instead.   
 
The prognostic influence of mutant status on survival outcomes were 
analysed using Cox proportional hazards modelling and described using 
hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for factors 
known to be prognostic or likely to interact with Bstatus.  In COIN and 
FOCUS: WHO performance status (2 vs 0/1); primary tumour resected (yes 
vs no); PTL (right colon vs other); platelet count (< vs ≥ 400,000/Pl); peritoneal 
metastases (present vs absent) and mismatch repair (MMR) status. In 
PICCOLO, adjustment was made for: response to previous therapy; 
performance status; peritoneal metastases; primary tumour resected and 
PTL. As these factors individually interact with prognosis, adjusted values are 
reported primarily but unadjusted values are provided. 
 
KaplanBMeier (KM) curves were plotted. For response endpoints, odds ratios 
(ORs) and 95% CIs were estimated from logistic regression models for the 
effect of Bmutant status, adjusted for the markers previously described. 
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(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
 status was available for 787/2135 (36.9%) patients in FOCUS, 
1284/1630 (78.8%) in COIN and 459/511 (89.8%) in PICCOLO 
(Supplementary Figure 1). The Bmutant prevalence was consistent with 
published values (FOCUS 61/787 [7.8%], COIN 130/1284 [10.1%], PICCOLO 
40/459 [8.7%]). mutant patients were more likely than wildBtypes to be 
female, have rightBsided PTL, have peritoneal or nodal metastases, but less 
likely to have lung metastases. Bmutant tumours were more likely to 
have dMMR than wildBtype tumours (12.6% vs 3.0%, p<0.001). 8/2530 (0.3%) 
patients’ tumours had dual mutations in both  and 	(Table 1) 
 
 )%
*(((
 
Bmutant status was a significant prognostic marker for OS in both firstB
line studies (COIN 9.8 vs 16.6 months, unadjusted HR =1.78 [1.46B2.17], 
p<0.001; FOCUS 10.9 vs 16.2 months, unadjusted HR=1.55 [1.18B2.04], 
p=0.030)(Table 2). Combining these data [n=2071] gave a median OS of 10.8 
vs 16.4 months (HR=1.49 [1.23B1.80] p<0.001)(Supplementary Figure 2). 
 
The prognostic impact of clinicopathological characteristics associated with 
Bmutant status that may interact with survival were explored in a 
univariate and multivariate analysis (Supplementary Table 1). Following 
adjustment, Bmutant status remained a significant prognostic marker in 
both trials (COIN adjusted HR =1.51 [1.19B1.91], p<0.001; FOCUS adjusted 
HR=1.44 [1.04B2.00], p=0.030)(Table 2). Given the demonstrated prognostic 
effect of clinicopathological factors associated with Bmutant status all 
subsequent analyses are adjusted. 
 
There was no evidence that Bmutant patients had inferior OS with a 
planned treatment break when firstBline treatment has not yet failed. COIN, 
which compared continuous or intermittent chemotherapy strategies, found 
that intermittent chemotherapy in the entire population was nonBinferior for OS 
(adjusted HR=1.04 [0.98–1.10], p=0.16).[19] In Bmutant patients this was 
also the case (adjusted HR=0.97 [0.80–1.17], p=0.75) (Supplementary Figure 
3). 
 
OS was improved in COIN for those who received subsequent secondBline 
chemotherapy compared with those without, regardless of Bstatus 
(Bmutant 16.1 vs 7.8 months [HR=0.56, p=0.005]; wildBtype 21.1 vs 11.6 
months [HR=0.48, p<0.001]; interaction p=0.66) However Bmutant 
patients had worse OS whether treated with secondBline chemotherapy, 
(HR=1.91[1.36B2.69], p<0.001), or not (HR=1.44 [1.12B1.84], p=0.004), 
compared with wildBtypes. 
 
The impact of Bstatus on OS for the 459 patients treated with secondB
line irinotecan was examined in the PICCOLO trial. Whilst OS was shorter for 
Bmutant patients compared with  wildBtype, the difference did not 
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 7 
reach statistical significance: 6.7 vs 10.2 months (adjusted HR=1.21 [0.84B
1.76], p=0.31)(Supplementary Table 2 and Supplementary Figure 4). 

%*)%%*
((+%,
 
In contrast to its marked effect on OS, mutantstatus had modest or 
insignificant impact on the firstBline PFS and response endpoints. Although for 
patients treated with firstBline OxFP in COIN  Bmutant patients had an 
inferior 12Bweek RR (34.3% vs 47.5%, adjusted OR=0.58 [0.37B0.92], 
p=0.020), the differences in DCR and PFS were not significant (DCR 59.2% 
vs 72.0%, adjusted OR=0.76 [0.49B1.20], p=0.24; PFS 5.7 vs. 6.3 months, 
adjusted HR=1.14 [0.91B1.42], p=0.26)(Table 2).  
 
Similarly for patients treated with firstBline combination chemotherapy in 
FOCUS, there were no differences in efficacy endpoints in Bmutant 
compared with  wildBtype patients: PFS was 8.2 vs 8.8 months (adjusted 
HR=1.07 [0.69B1.67], p=0.75); RR was 43.7% vs 43.1% (adjusted OR=1.09 
[0.45B2.65], p=0.85); DCR was 68.9% vs 69.9% (adjusted OR=1.01 [0.36B
2.84], p=0.97)(Table 2). There was no evidence of a differential effect of 
Bstatus according to regimen used (OxFU or IrFU, p=0.26). With firstB
line single agent 5FU in this trial (n=430), PFS was similar in Bmutant 
and Bwt patients (6.5 vs 6.7 months; adjusted HR=0.96 [0.60B1.52], 
p=0.30); RR was 17.2% vs 21.7% (adjusted OR=0.54 [0.17,1.72], p=0.30); 
DCR 48.3% vs 60.6% (adjusted OR=0.72 [0.27B1.94], p=0.52)(Supplementary 
Table 2). 
 
We examined the impact of chemotherapyBfree intervals on PFS in B
mutant patients in COIN. In all patients progression events in patients during 
chemotherapy breaks led to shorter PFS (adjusted HR=1.27 [1.21–1.33], 
p<0.001).[19] Bmutant patients were the only molecular subBgroup not to 
have a PFS disadvantage with intermittent chemotherapy (Bmutant PFS 
adjusted HR=1.09 [0.91–1.31], p=0.33;  wildBtype PFS adjusted 
HR=1.29 [1.21–1.37], p<0.001; interaction p=0.14)(Supplementary Figure 3).   
 
For patients treated with secondBline singleBagent irinotecan in PICOLLO 
there were no significant differences between Bmutant to wildBtype 
patients in PFS (3.5 vs 4.0 months, adjusted HR=1.01 [0.69B1.49], p=0.93), 
RR (5.0% vs. 8.1%, adjusted OR=0.56 [0.13B2.49], p=0.45)) and DCR (42.5% 
vs. 47.7% (adjusted OR=0.82[0.41B1.62],p=0.57)(Supplementary Table 2). 
 
Outcomes of Bmutant patients treated with antiBEGFR agents in COIN 
and PICCOLO have been previously reported,[9,18] and discussed in the 
Supplementary Material.  
 
%*)%)%((
 
Following progression on firstBline combination chemotherapy, Bmutant 
patients had markedly reduced PBPS compared with wildBtypes in both firstB
line trials. In COIN PPS was 3.2 months in Bmutant compared with 8.6 
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 8 
months in wildBtype patients (adjusted HR=1.72 [1.35B2.19], p<0.001). 
Similarly in FOCUS inferior PBPS was observed between Bmutant and 
wildBtypes (3.2 vs 8.1 months; adjusted HR=1.65 [1.03B2.67], p=0.038)(Table 
2). Combining this data PBPS was inferior in the Bmutant compared with 
the Bwt group (3.2 vs 8.6 months, HR=1.72 [1.35B2.19], 
p<0.001)(Supplementary Figure 5).  These marked differences were 
independent of firstBline treatment received (in COIN, OxFU vs OxCap 
p=0.53, in FOCUS OxFU vs IrFU p=0.91)(data not shown). Finally, following 
progression on singleBagent 5FU, PPS was reduced in the Bmutant 
group (3.5 vs 9.3 months; adjusted HR = 2.19[1.30B
3.69],p=0.003)(Supplementary Table 2), 
 
When other prognostic factors were tested in a combined multivariate model, 
a significant negative effect on PBPS was seen after firstBline chemotherapy 
for peritoneal metastases and dMMR status (peritoneal metastases HR=1.39, 
p<0.0001; dMMR HR=1.38, p=0.025). However the negative prognostic 
impact of peritoneal metastases and dMMR appears limited to the  wildB
type population, and neither factor impacted further on the poor PBPS seen in 
Bmutant patients (interaction p= 0.005 and p=0.05 respectively), 
suggesting that it is the Bmutation driving the observed poor outcomes 
(Supplementary Table 3). 
 
To explore the mechanism for inferior firstBline PBPS in Bmutant patients, 
we studied uptake of postBprogression therapies. In COIN, Bmutant 
patients were less likely to receive secondBline therapy after firstBline 
progression (33% vs. 51%, p=0.0002). Similarly, after completion of the 
FOCUS plan, which for all patients included two drugs (FU and either 
oxaliplatin or irinotecan, given over 1 or 2 lines), 123/401 (30.7%)  wildB
type and 3/29 (10.3%) Bmutant patients received subsequent salvage 
therapy (p=0.020).  
 
We then performed an exploratory analysis to ascertain whether the reduction 
in PBPS in Bmutant patients was due to rapid progression after initial 
firstBline benefit, rapid progression in patients who also rapidly progressed 
through firstBline treatment, or both. Table 3 shows the breakdown of patients 
by mutational status into 4 groups depending upon duration of firstBline PFS 
and subsequent PBPS: good PFS/ PBPS defined as greater than 6 months, 
poor PFS/PBPS defined as less than 6 months.  
 
Fewer Bmut patients had good firstBline PFS and good PBPS compared 
with wildBtype patients (24.3% vs 39.3%, p<0.001). Conversely there was a 
significantly higher proportion of Bmutant patients with very poor 
outcomes (both less than 6 months firstBline PFS and PBPS) compared with 
wildBtype patients (36.5% and 21.9% respectively, p<0.001). Thus, around a 
third of Bmutant patients not only fail to obtain useful benefit from firstB
line therapy but also rapidly progress thereafter. The difference in median 
survival of Bmutant patients between these two groups is 24.0 months to 
4.7 months. There were no significant differences in patient demographics 
between these two groups; however there was a trend towards lower median 
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 9 
age in the poor PFS/PBPS compared with the good PFS/PBPS group (61.9 vs 
65.2, p=0.07). 
 
Further difference in treatment patterns were observed: 67.5% of wildB
typepatients with good initial PFS also had a good PBPS compared with 
48.4% of the Bmutant patients (p<0.001). Whilst 47.4% of  wildB
type patients in spite of an initial poor firstBline PFS went onto have a greater 
than 6 months PBPS this was the case in just 26.6% of Bmutant patients.  
 
 
 at U
niversity of Birm
ingham
 on D
ecem
ber 20, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
 10
"!&!!$ 
 
This is the largest and most comprehensive clinical series assessing the 
outcomes of Bmutant patients treated with chemotherapy at different 
points of the aCRC pathway. In a careful multivariate analysis in a large, 
prospectively gathered cohort, Bmutation still conferred a worse 
prognosis and is not simply attributable to associated clinicoBpathological 
features.  
 
Within this dataset the poor outlook is not driven by chemoresistance. We 
observed no difference in the adjusted PFS or DCR between Bmutant 
and wildBtype patients receiving firstBline chemotherapy. There was also no 
difference in adjusted PFS or DCR between Bmutant and wildBtype 
patients who received secondBline irinotecan monotherapy. Results were 
consistent betweenboth firstBline trials, independent of chemotherapy strategy 
and other standard prognostic factors. OxFU is a commonly used firstBline 
therapy in aCRC, and was the firstBline regimen used in the majority of 
patients analysed herein, and indeed oxaliplatin may provide particular 
benefits in Bmutant patients [3, 21].  
 
Our analyses suggest instead that the point at which outcomesmarkedly 
diverge between Bmutant and wildBtypes is following progression on or 
after benefit from firstBline chemotherapy. Further investigation suggested that 
the observed significantly worse PBPS compared with wildBtypes may be due 
to the combined impact of two distinct patterns. Firstly Bmutant patients 
were more likely to rapidly progress through firstBline therapy and then 
subsequently rapidly deteriorate, either too unfit to receive subsequent 
treatment or progressing through that therapy. Secondly, Bmutant 
patients with an initial good outcome on firstBline chemotherapy were more 
likely to rapidly progress thereafter. Whilst around twoBthirds of wildBtype 
patients with good outcomes on initial therapy subsequently survive more 
than 6 months after progression on firstBline chemotherapy this fell to half of 
Bmutant patients. 
 
Although, the study is limited by relative small numbers of Bmutant 
patients compared to wildBtypes and findings should be interpreted with 
caution particularly subBgroup analyses, the data suggests that a significant 
proportion of Bmutant patients can obtain meaningful benefit from 
chemotherapy. Thus uniform nihilism about the impact of chemotherapy in 
deflecting the natural history of Bmutant aCRC is unjustified. 
Furthermore, Bmutant patients with disease control can be appropriately 
counselled about the safety of chemotherapy free intervals even though 
caution is required in the interpretation of this subBset analysis. However, 
postBprogression survival after firstBline progression is clearly worse in B
mutant patients and fewer receive secondBline therapy. It is important to 
emphasise that treating physicians were unaware of Bstatus, so this 
latter finding is not due to selection bias.  Thus, we suggest that extra 
vigilance is required when treating Bmutant patients, to promptly detect 
initial progression and then rapidly institute secondBline therapy in the 
knowledge that this has the capacity to significantly improve survival.  
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A third of Bmutant patients rapidly progress on and then after firstBline 
therapy with no obvious benefit from chemotherapy. These patients drive 
much of the observed poor outcomes of Bmutant aCRC and such 
aggressive clinical behaviour is what clinicians often have in mind when 
thinking about mutant aCRC patients. A biomarker is required to 
identify such patients who might benefit from an alternative therapeutic 
strategy, such as targeted therapy. The combination of a Binhibitor 
dabrafenib, a MEK inhibitor trametinib and an antiBEGFR agent panitumumab 
demonstrated an unconfirmed response rate of 30%.[22]  
 
Recent transcriptional analyses have subBdivided Bmutant aCRC into 2 
subBtypes with widely differing biology.[23] BM1 tumours constitute oneBthird of 
Bmutant cancers and are characterised by enrichment of a 	
signature and sensitivity to and inhibition. The other twoBthirds of 
Bmutant aCRC, the BM2 subBtype, are characterised by accelerated 
G2/M phase with low ATM with sensitivity to cdk1 inhibition. These checkpoint 
abnormalities could contribute to chemosensitivity by preventing DNA damage 
being repaired prior to mitosis. Thus, application of these signatures to these 
two clinically divergent groups of Bmutant patients appears warranted. 
Furthermore MMR testing should be encouraged in Bmutant aCRC 
patients and entry into RCT testing immunotherapy agents where available. 
 
This, the largest and most comprehensive analysis of chemotherapy 
outcomes in mutant CRC patients provides new and important 
information with clinical relevance. In summary, Bmutation confers a 
markedly worse prognosis independent of associated clinicopathological 
features. However, in some patients chemotherapy does provide meaningful 
improvements in outcome throughout treatment lines and translational efforts 
need to be made to identify them and those who appear to derive no benefit 
from chemotherapy. PostBprogression survival is worse in Bmutant 
patients and vigilance is required to ensure the appropriate delivery of 
treatment after firstBline progression. 
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Table 3: Breakdown of all patients by PFS and P-PS duration, then 
proportion of patients in each PFS/P-PS grouping by mutation status.  
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*Good PFS or P-PS is >6 months; Poor PFS or P-PS is  <6mths 
**9 pts had BRAF and RAS mut 
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